SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced financial results for the year ended December 31, 2025, and highlighted recent corporate accomplishments ...
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced financial results for the year ended December 31, 2025, and highlighted recent corporate accomplishments and milestones expected for 2026.
ALISO VIEJO, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and year ended December 31, 2025.
ALISO VIEJO, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the fourth quarter and year ended December 31, 2025.
CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
CHANDLER, Ariz., March 26, 2026 (GLOBE NEWSWIRE) -- VirTra, Inc . (Nasdaq: VTSI) (“VirTra” or the “Company”), a global provider of judgmental use-of-force and firearms training simulators, reported results for the fourth quarter and full year ended December 31, 2025. The financial statements are available on VirTra’s website and here .
CHANDLER, Ariz., March 26, 2026 (GLOBE NEWSWIRE) -- VirTra, Inc . (Nasdaq: VTSI) (“VirTra” or the “Company”), a global provider of judgmental use-of-force and firearms training simulators, reported results for the fourth quarter and full year ended December 31, 2025. The financial statements are available on VirTra’s website and here .
- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus –
- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participation from RA Capital Management, Special Situations Funds, and Invus –
Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies
Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies
- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum - - Life Sciences: R2 Secures 600‑System Commitment in China - - Spectrum: Recent network launches set to deliver benefits beginning in 2026 -
- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum - - Life Sciences: R2 Secures 600‑System Commitment in China - - Spectrum: Recent network launches set to deliver benefits beginning in 2026 -
NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results:
NASHVILLE, Tenn., March 26, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its fourth quarter results:
SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025.
SARATOGA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025.
SAN JOSE, Calif., March 26, 2026--Bloom Energy (NYSE: BE), a global leader in onsite power solutions, today announced the appointment of Simon Edwards as Chief Financial Officer, effective April 13, 2026. A seasoned finance executive with nearly two decades of experience scaling technology companies, Edwards brings a rare combination of operational rigor, systems leadership, and deep exposure to d...
SAN JOSE, Calif., March 26, 2026--Bloom Energy (NYSE: BE), a global leader in onsite power solutions, today announced the appointment of Simon Edwards as Chief Financial Officer, effective April 13, 2026. A seasoned finance executive with nearly two decades of experience scaling technology companies, Edwards brings a rare combination of operational rigor, systems leadership, and deep exposure to digital infrastructure that aligns with Bloom’s strength, market focus and strategy – to be a solutio
Gross Profit Increased to $28 Million in 2025 Compared to $25 Million in 2024, Representing a $3 Million (13%) Increase in Gross Profit Operating Cash Used in 2025 Amounted to $13 Million Compared to $18 Million in 2024, Representing a $5 Million (27%) Reduction in Cash Used in Operating Activities SKYX Raised $29 Million in Q1 2026 Investments from Fundamental Institutions SKYX Announced Collabor...
Gross Profit Increased to $28 Million in 2025 Compared to $25 Million in 2024, Representing a $3 Million (13%) Increase in Gross Profit Operating Cash Used in 2025 Amounted to $13 Million Compared to $18 Million in 2024, Representing a $5 Million (27%) Reduction in Cash Used in Operating Activities SKYX Raised $29 Million in Q1 2026 Investments from Fundamental Institutions SKYX Announced Collaboration with NVIDIA AI Ecosystem Connect Program, Expecting to Grow Its Collaboration with NVIDIA into
rarrarorro Wall Street closed sharply lower on Thursday as geopolitical uncertainty surrounding escalating U.S.-Iran tensions rattled investor sentiment and weighed heavily on risk assets. Markets struggled to find direction after Tehran rejected a U.S. proposal aimed at de-escalating the conflict, heightening concerns about a prolonged standoff and its broader economic implications. The technolog...
rarrarorro Wall Street closed sharply lower on Thursday as geopolitical uncertainty surrounding escalating U.S.-Iran tensions rattled investor sentiment and weighed heavily on risk assets. Markets struggled to find direction after Tehran rejected a U.S. proposal aimed at de-escalating the conflict, heightening concerns about a prolonged standoff and its broader economic implications. The technology-heavy Nasdaq Composite ( COMP:IND ) led the declines, falling 2.3%, as weakness across growth stocks intensified selling pressure. The benchmark S&P 500 ( SP500 ) dropped 1.7%, while the Dow Jones Industrial Average ( DJI ) shed 1%, reflecting broad-based losses across sectors. Energy markets remained a central focus for investors, as fears of supply disruptions pushed oil prices higher and reignited inflation concerns. Rising crude prices have the potential to complicate the global economic outlook, particularly if elevated costs persist and feed through to consumer prices. “The market is struggling to make sense of Iran war headlines,” said Seeking Alpha analyst Leo Nelissen. “ "While nobody seems to be able to judge just how likely a ceasefire is, most are fully aware that a prolonged spike in crude oil increases the stagflation risk.” Market Tracking ETFs: ( DIA ), ( DDM ), ( DOG ), ( DXD ), ( SDOW ), ( SPY ), ( VOO ), ( IVV ), ( RSP ), ( SSO ), ( UPRO ), ( SH ), ( SDS ), ( SPXU ), ( QQQ ), ( QQQM ), ( TQQQ ), ( QID ), and ( SQQQ ). What do you think is next for Social Security? Share your opinion in our user poll . More on markets 20 dividend stocks to watch as the Middle East conflict continues to shake markets OECD lifts G20 inflation outlook as rising energy prices impact global markets Exxon Mobil tops Nvidia in valuation amid the ongoing Middle East conflict Consumer staples stocks flash oversold signals as sector slides AI boom and an economic bust: Citrini Scenario gains momentum in prediction markets
May ICE NY cocoa (CCK26 ) on Thursday closed up +31 (+0.99%), and May ICE London cocoa #7 (CAK26 ) closed up +28 (+1.20%). Cocoa prices recovered from 2.5-week lows on Thursday and settled higher. Oversold conditions sparked technical short covering in cocoa futures on Thursday, following the steady decline...
May ICE NY cocoa (CCK26 ) on Thursday closed up +31 (+0.99%), and May ICE London cocoa #7 (CAK26 ) closed up +28 (+1.20%). Cocoa prices recovered from 2.5-week lows on Thursday and settled higher. Oversold conditions sparked technical short covering in cocoa futures on Thursday, following the steady decline...
May arabica coffee (KCK26 ) on Thursday closed down -8.45 (-2.67%), and May ICE robusta coffee (RMK26 ) closed down -33 (-0.91%). Coffee prices retreated on Thursday amid the outlook for a record Brazilian coffee crop. Marex Group Plc on Thursday projected a record 2026/27 Brazil coffee crop of 75.9...
May arabica coffee (KCK26 ) on Thursday closed down -8.45 (-2.67%), and May ICE robusta coffee (RMK26 ) closed down -33 (-0.91%). Coffee prices retreated on Thursday amid the outlook for a record Brazilian coffee crop. Marex Group Plc on Thursday projected a record 2026/27 Brazil coffee crop of 75.9...